The MPTP Mouse Model of Parkinson's Disease: The True, the False, and the Unknown

Parkinson's Disease

Volumn , Issue , 2008, Pages 147-158

  Jackson Lewis, Vernice ^a   Przedborski, Serge ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79953677529     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374028-1.00011-7     Document Type: Chapter

References (85)

1. Ali S.F., David S.N., Newport G.D. Age-related susceptibility to MPTP-induced neurotoxicity in mice. Neurotoxicology 1993, 14:29-34.
2. Anderson D.W., Neavin T., Smith J.A., Schneider J.S. Neuroprotective effects of pramipexole in young and aged MPTP-treated mice. Brain Res 2001, 905:44-53.
3. Barden H., Levine S. Histochemical observations on rodent brain melanin. Brain Res Bull 1983, 10:847-851.
4. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
5. Bezard E., Dovero S., Bioulac B., Gross C. Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice. Exp Neurol 1997, 148:288-292.
6. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp Neurol 1999, 155:268-273.
7. Bezard E., Dovero S., Imbert C., Boraud T., Gross C.E. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 2000, 38:363-368.
8. Bogerts B. A brainstem atlas of catecholaminergic neurons in man, using melanin as a natural marker. J Comp Neurol 1981, 197:63-80.
9. Bohn M.C., Cupit L., Marciano F., Gash D.M. Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. Science 1987, 237:913-916.
10. Bove J., Zhou C., Jackson-Lewis V., Taylor J., Chu Y., Rideout H.J., Wu D.C., Kordower J.H., Petrucelli L., Przedborski S. Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 2006, 60:260-264.
11. Bush W.D., Garguilo J., Zucca F.A., Albertini A., Zecca L., Edwards G.S., Nemanich R.J., Simon J.D. The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc Natl Acad Sci USA 2006, 103:14785-14789.
12. Castagnoli N., Chiba K., Trevor A.J. Potential bioactivation pathways for the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 1985, 36:225-230.
13. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984, 120:574-578.
14. Chiba K., Peterson L.A., Castagnoli K.P., Trevor A.J., Castagnoli N. Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Drug Metab Dispos 1985, 13:342-347.
15. Cohen G. Oxy-radical toxicity in catecholamine neurons. Neurotoxicology 1984, 5:77-82.
16. + binds to neuromelanin. Science 1986, 231:987-989.
17. D'Amato R.J., Alexander G.M., Schwartzman R.J., Kitt C.A., Price D.L., Snyder S.H. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. Nature 1987, 327:324-326.
18. D'Amato R.J., Alexander G.M., Schwartzman R.J., Kitt C.A., Price D.L., Snyder S.H. Neuromelanin: A role in MPTP-induced neurotoxicity. Life Sci 1987, 40:705-712.
19. D'Amato R.J., Benham D.F., Snyder S.H. Characterization of the binding of N-methyl-4-phenylpyridine, the toxic metabolite of the parkinsonian neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, to neuromelanin. J Neurochem 1987, 48:653-658.
20. Da Prada M., Kettler R., Keller H.H., Bonetti E.P., Imhof R. Ro 16-6491: A new reversible and highly selective MAO-B inhibitor protects mice from the dopaminergic neurotoxicity of MPTP. Adv Neurol 1987, 45:175-178.
21. Dauer W., Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003, 39:889-909.
22. Fahn S., Przedborski S. Parkinsonism. Merritt's Neurology 2005, 828-846. Lippincott Williams & Wilkins, New York. 11th edn. L.P. Rowland (Ed.).
23. Fedorow H., Tribl F., Halliday G., Gerlach M., Riederer P., Double K.L. Neuromelanin in human dopamine neurons: Comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005, 75:109-124.
24. Ferrante R.J., Schulz J.B., Kowall N.W., Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res 1997, 753:157-162.
25. Fleming S.M., Chesselet M.F. Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism. Behav Pharmacol 2006, 17:383-391.
26. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitin- proteasome system and {alpha}-synuclein. Proc Natl Acad Sci USA 2005, 102:3413-3418.
27. Fritz R.R., Abell C.W., Patel N.T., Gessner W., Brossi A. Metabolism of the neurotoxin in MPTP by human liver monoamine oxidase B. FEBS Lett 1985, 186:224-228.
28. Fuller R.W., Hahn R.A., Snoddy H.D., Wikel J.H. Depletion of cardiac norepinephrine in rats and mice by 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Pharmacol 1984, 19:2957-2960.
29. Gasser P.J., Lowry C.A., Orchinik M. Corticosterone-sensitive monoamine transport in the rat dorsomedial hypothalamus: Potential role for organic cation transporter 3 in stress-induced modulation of monoam-inergic neurotransmission. J Neurosci 2006, 26:8758-8766.
30. Giovanni A., Sieber B.A., Heikkila R.E., Sonsalla P.K. Correlation between the neostriatal content of the 1-methyl-4- phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J Pharmacol Exp Ther 1991, 257:691-697.
31. Giovanni A., Sieber B.-A., Heikkila R.E., Sonsalla P.K. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J Pharmacol Exp Ther 1994, 270:1000-1007.
32. Giovanni A., Sonsalla P.K., Heikkila R.E. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J Pharmacol Exp Ther 1994, 270:1008-1014.
33. Grimsby J., Toth M., Chen K., Kumazawa T., Klaidman L., Adams J.D., Karoum F., Gal J., Shih J.C. Increased stress response and beta-phenylethylamine in MAOB-deficient mice. Nat Genet 1997, 17:206-210.
34. Gupta M., Felten D.L., Gash D.M. MPTP alters central catecholamine neurons in addition to the nigrostriatal system. Brain Res Bull 1984, 13:737-742.
35. Gupta M., Gupta B.K., Thomas R., Bruemmer V., Sladek J.R., Felten D.L. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci Lett 1986, 70:326-331.
36. Hamre K., Tharp R., Poon K., Xiong X., Smeyne R.J. Differential strain susceptibility following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration acts in an autosomal dominant fashion: Quantitative analysis in seven strains of Mus musculus. Brain Res 1999, 828:91-103.
37. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
38. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and several of its analogues on the dopaminergic nigrostriatal pathway in mice. Neurosci Lett 1985, 58:133-137.
39. Heikkila R.E., Nicklas W.J., Vyas I., Duvoisin R.C. Dopaminergic toxicity of rotenone and the 1-methyl-4- phenylpyridinium ion after their stereotaxic administration to rats: Implication for the mechanism of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine toxicity. Neurosci Lett 1985, 62:389-394.
40. Heikkila R.E., Sieber B.A., Manzino L., Sonsalla P.K. Some features of the nigrostriatal dopaminergic neurotoxin 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol Chemic Neuropathol 1989, 10:171-183.
41. Hirsch E., Graybiel A.M., Agid Y.A. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature 1988, 334:345-348.
42. Hornykiewicz, Kish Biochemical pathophysiology of Parkinson's disease. Parkinson's Disease 1987, 19-34. Raven Press. M. Yahr, K.J. Bergmann (Eds.).
43. Irwin I., Finnegan K.T., DeLanney L.E., Di Monte D., Langston J.W. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: A critical reassessment. Brain Res 1992, 572:224-231.
44. Jackson-Lewis V., Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protocols 2007, 2:141-151.
45. Jackson-Lewis V., Jakowec M., Burke R.E., Przedborski S. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 1995, 4:257-269.
46. Jarvis M.F., Wagner G.C. Age-dependent effects of 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP). Neuropharmacology 1985, 24:581-583.
47. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 1984, 106:455-456.
48. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridinium by dopamine neurons explain selective toxicity. Proc Natl Acad Sci USA 1985, 82:2173-2177.
49. Johannessen J.N., Chiueh C.C., Herkenham M., Markey C.J. Relationship of the in vivo metabolism of MPTP to toxicity. MPTP: A Neurotoxin Producing a Parkinsonian Syndrome 1986, 173-190. Academic Press, Orlando. S.P. Markey, N. Castagnoli., A.J. Trevor, I.J. Kopin (Eds.).
50. Kindt M.V., Youngster S.K., Sonsalla P.K., Duvoisin R.C., Heikkila R.E. Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me- MPTP. Eur J Pharmacol 1988, 146:313-318.
51. Kitahama K., Denney R.M., Maeda T., Jouvet M. Distribution of type B monoamine oxidase immunoreactivity in the cat brain with reference to enzyme histochemistry. Neuroscience 1991, 44:185-204.
52. Kristufek D., Rudorfer W., Pifl C., Huck S. Organic cation transporter mRNA and function in the rat superior cervical ganglion. J Physiol 2002, 543:117-134.
53. Langston J.W., Ballard P., Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
54. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999, 46:598-605.
55. Mandel R.J., Spratt S.K., Snyder R.O., Leff S.E. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 1997, 94:14083-14088.
56. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984, 311:464-467.
57. Marsden C.D. Pigmentation in the nucleus substantiae nigrae of mammals. J Anat 1961, 95:256-261.
58. Meredith G.E., Totterdell S., Petroske E., Santa C.K., Callison R.C., Lau Y.S. Lysosomal malfunction accompanies alpha-synuclein aggregation in a progressive mouse model of Parkinson's disease. Brain Res 2002, 956:156-165.
59. Miller D.B., Ali S.F., O'Callaghan J.P., Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 1998, 844:153-165.
60. Moeller J.R., Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson's disease and normal ageing. Brain 1997, 120:2197-2206.
61. Muthane U., Ramsay K.A., Jiang H., Jackson-Lewis V., Donaldson D., Fernando S., Ferreira M., Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1 mice. Exp Neurol 1994, 126:195-204.
62. + (1-methyl-4-phenylpyridine) is a neurotoxin to dopamine-, norepinephrine- and serotonin-containing neurons. Eur J Pharmacol 1987, 136:31-37.
63. Przedborski S., Tieu K. Toxic animal models. Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics 2005, 196-221. Cambridge, New York. M.F. Beal, A.E. Lang, A. Ludolph (Eds.).
64. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. J Neurosci 1992, 12:1658-1667.
65. Przedborski S., Jackson-Lewis V., Naini A., Jakowec M., Petzinger G., Miller R., Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem 2001, 76:1265-1274.
66. Riachi N.J., LaManna J.C., Harik S.I. Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain. J Pharmacol Exp Ther 1989, 249:744-748.
67. Saper C.B., Petito C.K. Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. Brain 1982, 105:87-101.
68. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
69. Schmued L.C., Hopkins K.J. Fluoro-Jade: Novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol Pathol 2000, 28:91-99.
70. Schmued L.C., Albertson C., Slikker W. Fluoro-Jade: A novel fluorochrome for the sensitive and reliable histochemical localization of neuronal degeneration. Brain Res 1997, 751:37-46.
71. Sedelis M., Schwarting R.K., Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav Brain Res 2001, 125:109-125.
72. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral- striatal projections by MPTP. Brain Res 1990, 527:7-20.
73. Shang T., Uihlein A.V., Van A.J., Kalyanaraman B., Hillard C.J. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J Neurochem 2003, 85:358-367.
74. Shults C.W. Lewy bodies. Proc Natl Acad Sci USA 2006, 103:1661-1668.
75. Smith P.D., Crocker S.J., Jackson-Lewis V., Jordan-Sciutto K.L., Hayley S., Mount M.P., O'Hare M.J., Callaghan S., Slack R.S., Przedborski S., Anisman H., Park D.S. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2003, 100:13650-13655.
76. Sotelo C., Javoy F., Agid Y., Glowinski J. Injection of 6-hydroxydopamine in the substantia nigra of the rat. I. Morphological study. Brain Res 1973, 58:269-290.
77. Staal R.G., Sonsalla P.K. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. J Pharmacol Exp Ther 2000, 293:336-342.
78. Takahashi H., Ohama E., Suzuki S., Horikawa Y., Ishikawa A., Morita T., Tsuji S., Ikuta F. Familial juvenile parkinsonism: Clinical and pathologic study in a family. Neurology 1994, 44:437-441.
79. Takatsu H., Wada H., Maekawa N., Takemura M., Saito K., Fujiwara H. Significant reduction of 125 I-meta-iodobenzylguanidine accumulation directly caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydroxypyridine, a toxic agent for inducing experimental Parkinson's disease. Nucl Med Commun 2002, 23:161-166.
80. Tatton W.G., Greenwood C.E., Seniuk N.A., Salo P.T. Interactions between MPTP-induced and age-related neuronal death in a murine model of Parkinson's disease. Can J Neurol Sci 1992, 19:124-133.
81. Vila M., Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med 2004, 10(Suppl):S58-sS62.
82. Westlund K.N., Denney R.M., Kochersperger L.M., Rose R.M., Abell C.W. Distinct monoamine oxidase A and B populations in primate brain. Science 1985, 230:181-183.
83. Westlund K.N., Denney R.M., Rose R.M., Abell C.W. Localization of distinct monoamine oxidase B cell populations in human brainstem. Neuroscience 1988, 25:439-456.
84. Zecca L., Tampellini D., Gerlach M., Riederer P., Fariello R.G., Sulzer D. Substantia nigra neuromelanin: Structure, synthesis, and molecular behaviour. Mol Pathol 2001, 54:414-418.
85. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.